The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.

The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.

598890 Disclosed herein are compounds of formula (I) U1-M-U2 wherein the variables are defined in the specification the use of said compounds in the treatment of cancer specifically by sensitising a cell to an apoptotic signal. Additionally said compounds may be used for sequential or concomitant use with a pharmaceutical compound which induces an apoptotic signal such as cytarabine fludarabine 5-fluoro-2'-deoxyuridine 5 gemcitabine methotrexate bleomycin cisplatin cyclophosphamide adriamycin (d...

The disclosure relates to compounds and compositions for bone formation fracture treatment bone grafting bone fusion cartilage maintenance and repair and methods related thereto. In certain embodiments the disclosure relates to compositions comprising one or more compound(s) disclosed herein such as clotrimazole honokiol magnolol tacrolimus pimecrolimus sirolimus everolimus temsirolimus spironolactone fluticasone fluticasone propionate fluticasone furoate linezolid telmisartan chlorambucil retin...